Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis

L J W Canham; A Manara; J Fawcett; M Rolinski; A Mortimer; K E A Inglis; D A Cottrell

doi:10.1016/j.msard.2018.05.014

Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis

L J W Canham, A Manara, J Fawcett, M Rolinski, A Mortimer, K E A Inglis, D A Cottrell

Research output: Contribution to journal › Article (Academic Journal) › peer-review

19 Citations (Scopus)

593 Downloads (Pure)

Abstract

We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated.

Original language	English
Pages (from-to)	38-41
Number of pages	4
Journal	Multiple Sclerosis and Related Disorders
Volume	24
Early online date	16 May 2018
DOIs	https://doi.org/10.1016/j.msard.2018.05.014
Publication status	Published - Aug 2018

Bibliographical note

Access to Document

10.1016/j.msard.2018.05.014

Full-text PDF (accepted author manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://www.sciencedirect.com/science/article/pii/S2211034818301743?via%3Dihub. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 243 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{16c7e192c81f4fec81da231fc4436cb6,

title = "Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis",

abstract = "We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated.",

author = "Canham, \{L J W\} and A Manara and J Fawcett and M Rolinski and A Mortimer and Inglis, \{K E A\} and Cottrell, \{D A\}",

note = "Copyright {\textcopyright} 2018. Published by Elsevier B.V.",

year = "2018",

month = aug,

doi = "10.1016/j.msard.2018.05.014",

language = "English",

volume = "24",

pages = "38--41",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis

AU - Canham, L J W

AU - Manara, A

AU - Fawcett, J

AU - Rolinski, M

AU - Mortimer, A

AU - Inglis, K E A

AU - Cottrell, D A

PY - 2018/8

Y1 - 2018/8

N2 - We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated.

AB - We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated.

U2 - 10.1016/j.msard.2018.05.014

DO - 10.1016/j.msard.2018.05.014

M3 - Article (Academic Journal)

C2 - 29885597

SN - 2211-0348

VL - 24

SP - 38

EP - 41

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

ER -

Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis

Abstract

Bibliographical note

Access to Document

Handle.net

Fingerprint

Cite this